SCHEMBL3129409

SCHEMBL3129409

COc1ccc(-c2nc(-c3cc(OC)cc(OC)c3)[nH]c2C(N)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 1/20 0.51
CHEK2 O96017 5/20 0.49
PARP1 P09874 3/20 0.49
PLA2G2A P14555 1/20 0.49
ALOX15 P16050 1/20 0.49
PTGS2 P35354 1/20 0.49
NOX1 Q9Y5S8 1/20 0.49
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 2/20 0.48
HPGD P15428 2/20 0.48
MEN1 O00255 1/20 0.48
CYP1A2 P05177 1/20 0.48
GLA P06280 1/20 0.48
CYP2C19 P33261 1/20 0.48
GFER P55789 1/20 0.48
KMT2A Q03164 1/20 0.48
TGFBR1 P36897 1/20 0.46
MAP2 P11137 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3120095 0.93 NOX1 (0.56) SMPD3CHEK2PARP1PLA2G2AALOX15
SCHEMBL3126479 0.90 PARP1 (0.58) CHEK2PARP1PLA2G2AALOX15PTGS2
SCHEMBL3120707 0.88 KDM4E (0.62) CHEK2PARP1PLA2G2AALOX15PTGS2
SCHEMBL3125676 0.88 NOX1 (0.51) SMPD3CHEK2PARP1PLA2G2AALOX15
SCHEMBL3127609 0.87 MAP2 (0.52) CHEK2PARP1PLA2G2AALOX15PTGS2
SCHEMBL3130904 0.87 TGFBR1 (0.60) CHEK2PARP1PLA2G2AALOX15PTGS2
SCHEMBL3119962 0.85 HPGD (0.60) CHEK2PARP1PLA2G2AALOX15PTGS2
SCHEMBL3118971 0.84 MAP2 (0.50) CHEK2PARP1PLA2G2AALOX15PTGS2
SCHEMBL3127504 0.83 NPY5R (0.50) PARP1PLA2G2AALOX15PTGS2MAPT
SCHEMBL3418406 0.81 TEK (0.50) CHEK2PARP1PLA2G2AALOX15PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 EP disclosed
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 EP disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 WO disclosed
EP-2170849-A1 OXAZOLE TYROSINE KINASE INHIBITORS Sareum Limited (GB) 2010-04-07 EP disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 WO disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 SMPD3 4667/4885CHEK2 179/4885PARP1 2897/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 SMPD3 4667/4885CHEK2 179/4885PARP1 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.